Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer

Published:2017-07-14 Issue:4 Volume:12 Page:555-562
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Lamb Yvette N.,Scott Lesley J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s11523-017-0519-0/fulltext.html

Reference31 articles.

1. American Cancer Society. Non-small cell lung cancer. 2016. http://www.cancer.org /. Accessed 28 Jun 2017.

2. World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012. http://globocan.iarc.fr /. Accessed 28 Jun 2017.

3. Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.

4. Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015;16:e447–59.

5. National Comprehensive Cancer Network. NCCN guidelines version 4.2017: non-small cell lung cancer. 2017. http://www.nccn.org . Accessed 28 Jun 2017.

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Supramolecular self-assembly strategy for the enhanced solubility/dissolution rate and anti-cancer efficacy of osimertinib: Insights from multi-component crystals to drug chemistry;Chemical Engineering Science;2024-11

2. The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis;The Clinical Respiratory Journal;2024-04

3. 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-11

4. Electrochemiluminescent CdS Quantum Dots Biosensor for Cancer Mutation Detection at Different Positions on Linear DNA Analytes;Analytical Chemistry;2023-09-08

5. Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study;International Journal of Radiation Oncology*Biology*Physics;2023-09